About ArcherDX
ArcherDX is a Healthcare company based in Boulder (United States) founded in 2013 by John Iafrate and Long Phi Le, and was acquired by Invitae in June 2020. Molecular cancer diagnostic products are developed using patented AMP technology. ArcherDX has raised $152.6 million across 3 funding rounds from investors including Invitae, Driehaus and Perceptive Advisors. The company has 429 employees. ArcherDX has completed 1 acquisition, including Baby Genes. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its legal entity is ARCHERDX, INC. Its competitors include Guardant Health, Natera and Foundation Medicine; 3 of its 3 listed competitors have raised funding.
Company details
ArcherDX was founded in 2013 in Boulder, United States, within the biotechnology sector. Patented Anchored Multiplex PCR (AMP) technology is employed to create in-vitro diagnostics and Personalized Cancer Monitoring products for identifying solid tumor biomarkers. Operations focus on molecular diagnostics for oncology, with a product pipeline that includes ArcherMET, NTRK CDx, and Fusion Plex.
- Headquarters Boulder, United States
- Employees 429
- Founders John Iafrate, Long Phi Le
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website archerdx.com
- Social LinkedIn X
- Acquired by Invitae (Jun 2020)
- Legal Name Archerdx, Inc.
Funding Insights of ArcherDX
ArcherDX has successfully raised a total of $152.6M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $55 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $152.6M
- Total Rounds 3
- Last Round Series C — $55M
- First Round $37.6M
(Mar 2018)
- Investors Count 9
All 3 funding rounds of ArcherDX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $55M | Series C | – | Perceptive Advisors | |
| May 2019 | $60M | Series B | – | Perceptive Advisors | |
| Mar 2018 | $37.6M | Series A | – | Boulder Ventures, PBM Capital |
10 investors in total: 10 institutional.
Investors in ArcherDX
ArcherDX has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Invitae, Driehaus and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| soleuscapital.com | ||||
PE firm investing in the US | pbmcap.com | Charlottesville, United States | ||
Venture capital is offered by Boulder Ventures for innovative companies. | boulderventures.com | Boulder, United States | ||
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Growth stage tech & life sciences focused VC Firm investing in Asia and the US | sandscapitalventures.com | Arlington, United States | ||
Fund investment management services are provided by Driehaus in Chicago. | 1982 | driehaus.com | Chicago, United States | |
Diversified asset management services are provided to investors. | 2007 | arrowmarkpartners.com | Denver, United States | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Home-based genetic tests for detecting diseases are provided to individuals. | 2010 | invitae.com | San Francisco, United States |
Investor details for ArcherDX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ArcherDX
24 people are tracked at ArcherDX (9 in leadership, 5 in board & advisors, 10 in team); the tracked headcount is 429.
| Name | Role | Group |
|---|---|---|
John Iafrate | Co-Founder | Leadership |
Long Phi Le | Co-Founder | Leadership |
Josh Stahl | COO & Chief Scientific Officer | Leadership |
Todd Druley | Chief Medical Officer | Leadership |
Maggie Chapman | VP, Product Marketing | Leadership |
Chinmay Sheth | Director, Oncology Product Management | Leadership |
James Ashby | Director of Quality Assurance | Leadership |
Jeffrey Falk | Director, IVD Companion Diagnostics & Assay Development | Leadership |
Michael Schwimmer | Senior Director Customer Success | Leadership |
Steve Kafka | Chariman | Board & advisors |
Paul Manning | Director | Board & advisors |
Jason Ryan | Director | Board & advisors |
Kyle Lefkoff | Director | Board & advisors |
Marvin H. Caruthers | Director | Board & advisors |
Young Pham | CloudLIMS Validation Project Lead | Team |
Ben Carver | General Counsel | Team |
Ryan Walters | EVP of Research & Development | Team |
Karen Fritschen | EVP of Human Resources | Team |
Géraldine BAMBA | Field Application Scientist | Team |
Sandra Close | EVP of Quality, Regulatory & Business Strategy | Team |
4 more people are available in the full profile.
Complete people profiles for ArcherDX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ArcherDX
ArcherDX has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Baby Genes.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Genomic diagnostic solutions for neonates and carrier testing are provided. | babygenes.net | Golden, United States | 2013 | Jan 2019 | •••• |
Complete acquisition details for ArcherDX
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ArcherDX
5 dated milestones of ArcherDX across 7 years, from founding to its latest funding, stage changes and deals.
- Founded ArcherDX is founded.
- Funding First funding round of $37.6M.
- Acquisition Acquires Baby Genes.
- Funding Latest funding round, Series C, of $55.0M.
- Exit Acquired by Invitae.
Competitors of ArcherDX
ArcherDX has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Foundation Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. |
Detailed competitors of ArcherDX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ArcherDX
The website of ArcherDX (archerdx.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 123% vs previous month
Websites whose visitors overlap most with ArcherDX. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
reactome.org | reactome.org | 100% | #298,062 | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as ArcherDX (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Archerdx
Complete news archive for ArcherDX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ArcherDX
ArcherDX was founded in 2013 and raised its 1st funding round 5 years after it was founded.
ArcherDX is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
ArcherDX is a funded company, having raised a total of $152.6M across 3 funding rounds to date. The company's 1st funding round was a Series A of $37.6M, raised on Mar 2018.
ArcherDX has 429 employees.
ArcherDX was founded in 2013 in Boulder, United States, within the biotechnology sector. Patented Anchored Multiplex PCR (AMP) technology is employed to create in-vitro diagnostics and Personalized Cancer Monitoring products for identifying solid tumor biomarkers. Operations focus on molecular diagnostics for oncology, with a product pipeline that includes ArcherMET, NTRK CDx, and Fusion Plex.
ArcherDX's top competitors include Guardant Health, Foundation Medicine and Natera.
ArcherDX has made 1 acquisition, including Baby Genes.
ArcherDX has 10 investors. Key investors include Invitae, Driehaus, Perceptive Advisors, ArrowMark Partners, and Soleus Capital.
ArcherDX operates through Archerdx, Inc..
Yes. ArcherDX was acquired by Invitae in June 2020.